Actionable news
All posts from Actionable news
Actionable news in ZIOP: ZIOPHARM Oncology Inc,

Wells Fargo Maintains Underperform On ZIOPHARM Oncology Inc. (ZIOP) Following 1Q16 Update

In a research report issued yesterday, Wells Fargo analyst Jim Birchenough reiterated an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.00 to $8.00, after the oncology biotech firm announced first-quarter operating results and provided an update on its clinical progress.

Birchenough wrote, “We are maintaining our Underperform rating on shares of ZIOP following review of its 1Q16 update. With near term focus on the update for Ad-RTS-IL12 in GBM, we believe that patient numbers are insufficient to make any...